The software company hiding inside a mammoth
How a tool built to bring back the woolly mammoth became a bet on the least glamorous problem in medicine: manufacturing.
In 2022, the biotech world was fixated on a headline-grabbing idea: reviving the woolly mammoth. The company behind it, Colossal Biosciences, needed enormous amounts of software to manage the genomic data that de-extinction demands. What it built along the way turned out to be valuable in its own right. That software became Form Bio.
Spun out of Colossal in September 2022 with a $30 million Series A led by JAZZ Venture Partners, Form Bio set out with a deceptively simple premise: genetic medicine is, in large part, a software problem. Designing a gene therapy, predicting how it will behave, and proving it can be made the same way twice are all computational challenges long before they are wet-lab ones.
The company is based in Austin, Texas, with roots in Dallas, and runs an unusual dual co-CEO structure. Andrew Busey - who earlier in his career worked on Mosaic, the first widely used web browser, and built iChat, one of the first web-based chat systems - shares the top job with Kent Wakeford, formerly Colossal's chief operating officer. Colossal CEO Ben Lamm is a co-founder.
Rather than chase the flashiest corner of biotech, Form Bio aimed at the part where most therapies quietly die: getting them manufactured consistently, at scale, and in a way regulators will accept.
Form Bio is the missing piece in scientific discovery.- Ben Lamm, Co-Founder
Modeling billions of designs before the bench
At its core, Form Bio offers a computational platform that lets scientists model and evaluate enormous numbers of possible therapeutic vector designs in silico - on a computer - to maximize efficacy, safety, and manufacturability. Instead of building candidates one at a time and testing them in the lab, researchers can screen designs computationally and carry forward only the ones likely to succeed.
The focus is on adeno-associated virus (AAV) gene therapies, the delivery vehicles behind many of today's cell and gene therapy programs. Form Bio's tools handle genome assembly and reconstruction, genome integrity analysis, AI-powered codon optimization, capsid analysis, and the general work of turning messy genomic data into decisions. It is cloud-based, collaborative, and built to sit across the full development lifecycle - from early design through manufacturing and regulatory submission.
Why gene therapies fail
The problem Form Bio targets is specific and expensive. In cell and gene therapy, the therapy a scientist designs and the therapy that can actually be manufactured at scale are not always the same molecule. Small inconsistencies - partial capsids, host-cell contaminants, CpG islands, genome-integrity defects - can derail a program late, after millions of dollars and months of work.
of FDA rejections in cell & gene therapy are triggered by quality or manufacturing issues - not the underlying science. Manufacturing, not discovery, is the bottleneck.
Three tools for one bottleneck
Form Bio's product line reads like a pipeline: predict problems early, optimize the design, then prove consistency at the end.
FormManufacturing
An end-to-end platform to predict, optimize, and monitor manufacturability for cell & gene therapies - from initial construct design through commercial scale-up - pairing AI-driven design optimization with deep genomic characterization.
FORMsightAI
Screens thousands of vector constructs in silico to flag manufacturing risks - partial capsids, host contaminants, CpG islands - before they ever reach the lab, improving yield and reducing cost.
FormBatchQC
Quantifies genome integrity, detects impurities, and provides defensible regulatory evidence of lot-to-lot consistency from tech transfer through commercialization.
Computational Platform
Cloud-based data management, workflows, visualization, and bioinformatics services - genome assembly, integrity analysis, codon optimization, and capsid analysis in one collaborative environment.
The customers on the other side
Form Bio sells to drug developers, biomanufacturers, pharma companies, and research institutions - the organizations carrying gene-therapy programs through preclinical development and toward the clinic. Publicly referenced customers and collaborators include Taysha Gene Therapies, Solid Biosciences, and Coave Therapeutics, alongside the nonprofit Cure Rare Disease and academic partner Weill Cornell Medicine. Its founding customer was Colossal itself.
Drug developers
Cell & gene therapy companies designing AAV vectors and needing to de-risk them before scale-up.
Biomanufacturers
Teams responsible for making therapies consistently, batch after batch, under regulatory scrutiny.
Pharma
Larger organizations integrating computational design and characterization into existing pipelines.
Research institutions
Academic and nonprofit labs advancing genome engineering and rare-disease therapeutics.
Software people who learned biology
Plenty of companies offer bioinformatics tools, and plenty offer AI for drug discovery. Form Bio's distinguishing bet is where it aims: not at discovering new targets, but at the manufacturing and characterization layer that determines whether a therapy can be produced and approved at all. It deliberately fuses traditional software engineering culture with molecular biology and drug-development expertise, rather than treating one as an afterthought to the other.
Against in-house bioinformatics teams and contract manufacturers' analytical services - the usual build-or-buy alternatives - Form Bio's argument is that manufacturability can be predicted computationally and turned into defensible, regulator-ready evidence. Competitors in the broader space include DNAnexus, Benchling, and AI-for-biology firms such as Insilico Medicine, but few frame the problem as squarely around manufacturing risk.
The potential to radically reduce costs while enhancing the speed and safety of cell and gene therapies.- Kent Wakeford, Co-CEO
Enterprise software, sold to science
Form Bio operates as a B2B enterprise software and services company. Revenue comes from platform access and from analytical and bioinformatics service engagements across the development lifecycle. The value proposition is concrete: fewer failed manufacturing runs, faster iteration, and cleaner regulatory documentation - each of which, in gene therapy, translates directly into saved time and money. The company employs roughly 36 people and has raised $30 million to date; it has not disclosed revenue or valuation figures publicly.
Where Form Bio fits
Cell and gene therapy is one of the fastest-moving frontiers in medicine, and also one of the most operationally fragile. As more therapies move from proof-of-concept toward commercialization, the manufacturing and quality layer becomes the choke point. Form Bio has positioned itself in that layer - between the science of what to make and the reality of making it - and in doing so has become an example of Austin's quieter turn toward deeptech, where hard-science startups sit alongside the city's better-known consumer and software scene.
Who built it
Andrew Busey
Kent Wakeford
Ben Lamm
How it happened
Spun out of Colossal Biosciences
Form Bio launches as an independent computational life sciences company with an oversubscribed $30M Series A led by JAZZ Venture Partners.
FORMsightAI announced
An AI solution set to predict and optimize manufacturability for cell & gene therapies debuts, screening constructs before they reach the lab.
Team expansion
The company scales its Austin and Dallas headcount as it builds out the platform and its go-to-market.
FormManufacturing launches
An end-to-end platform for AI-driven design and manufacturing of genetic medicines debuts and is showcased at the ASGCT Annual Meeting in Boston.
Critical to paving the way for advances in bioengineering.- George Church, Professor, Harvard
Common questions
What does Form Bio do?
Form Bio builds AI-driven software and analytical services that help scientists design, characterize, and manufacture genetic medicines - especially AAV-based cell and gene therapies - by modeling and screening designs computationally before lab work begins.
Who founded Form Bio and when?
It was founded in 2022 as a spinout of Colossal Biosciences, co-founded by Andrew Busey and Kent Wakeford, who serve as co-CEOs, along with Colossal CEO Ben Lamm.
How much funding has Form Bio raised?
Form Bio raised a $30 million Series A round in 2022, led by JAZZ Venture Partners with participation from investors including Thomas Tull.
What problem does Form Bio solve?
It targets the manufacturing bottleneck in cell and gene therapy - roughly 74% of FDA rejections tied to quality or manufacturing - by predicting and optimizing manufacturability in silico before therapies reach the lab.
Who are Form Bio's customers?
Cell and gene therapy developers, biomanufacturers, pharma companies, and research institutions, including referenced names like Taysha Gene Therapies, Solid Biosciences, Coave Therapeutics, Cure Rare Disease, and Weill Cornell Medicine.